Skip to main content
Quest Diagnostics

Evaluation of a Novel Home-Based Pathway to Support Early Detection and Diagnosis of Alzheimer’s Disease

AAIC 2025

Alzheimer’s Association International Conference

Toronto, Canada, July 27-31 , 2025

Poster presentation: Evaluation of a Novel Home-Based Pathway to Support Early Detection and Diagnosis of Alzheimer’s Disease

Authors: Atkins KJ, Brailow T, Tsoy E, Weigand A, Racke M, Larsen J, Reck-Rivera C, Windon C, Dilworth-Anderson P, Rabinovici G, Possin KL

Medical Specialty: Neurology

Related content

On-Demand Webinar
The Evolving Role of Biomarkers in Alzheimer’s Evaluation
Audio Podcast
Integrating Blood-Based Biomarkers for Alzheimer’s Risk Assessment
Test FAQ
Quest Dementia Testing
Publication
Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology
Conference Presentation
Combination of Plasma Beta Amyloid 42/40 and p-tau217 in the Assessment of Alzheimer’s Disease
Audio Podcast
Assessing for Alzheimer’s Disease with Quest Diagnostics

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.